Off-Label Ltd

subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link | subglobal1 link
subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link | subglobal2 link
subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link | subglobal3 link
subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link | subglobal4 link
subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link | subglobal5 link
subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link | subglobal6 link
subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link | subglobal7 link
subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link | subglobal8 link

US search results

Number of records found 3

Select ID for details Off-label therapeutic category Subcategory Drug Reported off-label use
1069 Genito-Urinary & Renal Bladder Tolterodine tartrate Treatment-naive children with non-neurogenic overactive bladder
4546 Genito-Urinary & Renal Bladder Tolterodine tartrate Randomized controlled trials designed to evaluate the efficacy and safety of tolterodine extended release (2 mg daily) for the treatment of children with urinary urge incontinence suggestive of detrusor overactivity (SUBPOP)
7515 Genito-Urinary & Renal Bladder Tolterodine tartrate Randomized controlled trial to compare the efficacy of tolterodine treatment (1 mg twice daily) plus behavioral modification, with behavioral modification alone in a total of seventy-two children with nonneurogenic nonanatomic voiding dysfunction (The investigators conclude that tolterodine plus behavioral modification for voiding dysfunction in children without neurological or anatomical abnormality can be recommended as a first line treatment before invasive evaluation)

Definition of descriptors (where appropriate):

*The reported drug was used as part of a combined therapy regimen

SUBPOP Variability in response may represent responding/nonresponding patient subgroups
ALERT Potential for remarkable and/or significant toxicity

 

 

 

About Us |Privacy Policy | Contact Us | ©2008 Off-Label Ltd